Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

24.88 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
News headline image
Hims & Hers Health Stock Slips After Surging 50% In A Month ↗
Hims & Hers Health Inc (NYSE: HIMS) shares are pulling back Monday morning, giving back a portion of last week's sharp rally. 
Via Benzinga
News headline image
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks ↗
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending. 
Via The Motley Fool
MarketBeat Week in Review – 03/09 - 03/13 ↗
Despite continued volatility, stocks have stayed resilient as investors navigate the fog of war. The story is largely about oil. When the price of crude oil goes up, stocks go down and vice versa.... 
Via MarketBeat
News headline image
The Great Pivot: How the Novo Nordisk Deal Transformed Hims & Hers (HIMS) into a Healthcare Powerhouse
As of March 13, 2026, the healthcare landscape has witnessed one of the most significant pivots in the history of digital health. Hims & Hers Health, Inc. (NYSE: HIMS) has officially transitioned from... 
Via Finterra
Topics Economy
News headline image
Stock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit Taking ↗
On March 12, 2026, investors weighed profit-taking against a high-stakes pivot toward branded obesity drugs and telehealth growth. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Does This Deal Make Novo Nordisk Stock a Buy? ↗
Not many things have gone right for Novo Nordisk recently, but this is one of them. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
The New Era of Hims & Hers Health (HIMS): Navigating the Branded Obesity Drug Pivot
As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers... 
Via Finterra
News headline image
Why Hims & Hers Health (HIMS) Stock Is Surging In Thursday's Premarket ↗
HIMS stock jumps in Thursday premarket. Explore how the Novo Nordisk partnership and a 46% short float are driving Hims & Hers Health Inc (NYSE: HIMS) higher. 
Via Benzinga
News headline image
1 Value Stock with Exciting Potential and 2 We Ignore
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
These stocks are making the most noise in today's session. ↗
Via Chartmill
News headline image
Hims & Hers Stock Skyrockets as Landmark Settlement with Novo Nordisk Ends Weight-Loss Drug War
The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant... 
Via MarketMinute
Topics Economy Intellectual Property Lawsuit
News headline image
HIMS Stock Jumps 14% – Barclays Says Market Is Underestimating Opportunity From New Products ↗
Brokerages have turned bullish on HIMS since its deal with Novo Nordisk earlier this week, with Barclays raising the stock’s price target to $29. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Short Seller Who Bet Against Hims & Hers Now Says Its CEO 'Wiped The Floor' With Novo Nordisk ↗
Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents. 
Via Stocktwits
Topics Bankruptcy Fraud Intellectual Property
News headline image
3 Big Reasons to Love Hims & Hers Health (HIMS)
Hims & Hers Health has gotten torched over the last six months - since September 2025, its stock price has dropped 55.2% to $23.21 per share. This may have i... 
Via StockStory
News headline image
Hims & Hers Names Kathryn Beiser as Chief Communications Officer
From Hims & Hers
Via Business Wire
News headline image
Asset Manager Exits Shares of Hims & Hers Health ↗
Hims & Hers Health has struggled, but it just inked a new partnership with Novo Nordisk. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal ↗
Via MarketBeat
News headline image
Disrupting the Pharmacy: A Deep-Dive into Hims & Hers Health (HIMS) in 2026
As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a... 
Via Finterra
Topics Artificial Intelligence Economy
News headline image
Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock ↗
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers
From Hims & Hers
Via Business Wire
From Red to Green: How Trump's Iran Endgame Sparked a Wall Street Comeback ↗
Via Chartmill
Topics Government
News headline image
HIMS Stock Rockets To Best Day Ever After Novo Nordisk Pact — Wall Street Upgrades Roll In As Shorts Lose $546M In One Day ↗
Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Stock Market Today, March 9: Hims & Hers Health Soars on Novo Nordisk Weight-Loss Drug Deal ↗
On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile. 
Via The Motley Fool
Topics Intellectual Property Lawsuit Stocks
Top stock movements in today's session. ↗
Via Chartmill
These stocks are making the most noise in today's session. ↗
Via Chartmill
News headline image
The Great 2026 Pivot: Tangible Assets Surge as Tech Giants Falter in Massive Sector Rotation
The financial landscape on March 9, 2026, has reached a critical tipping point, marking one of the most aggressive sector rotations in modern market history. As technology-heavy indices struggle to... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!
Via AB Newswire
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy? ↗
Hims & Hers stock traded more than 40% higher after the deal was announced. 
Via The Motley Fool
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.